Forest, Almirall COPD drug wins US FDA lung panel's backing
This article was originally published in Scrip
Executive Summary
Wanting to give patients with chronic obstructive pulmonary disease (COPD) another therapeutic option, advisers to the US FDA on 23 February backed approval of Forest Laboratories' and Almirall's experimental inhaled medicine aclidinium bromide, voting 12-2.